{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T13:21:36Z","timestamp":1794144096741,"version":"4.8.0"},"reference-count":77,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,4,5]],"date-time":"2024-04-05T00:00:00Z","timestamp":1712275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,4,5]],"date-time":"2024-04-05T00:00:00Z","timestamp":1712275200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100006364","name":"Institut National Du Cancer","doi-asserted-by":"publisher","award":["18-127"],"award-info":[{"award-number":["18-127"]}],"id":[{"id":"10.13039\/501100006364","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006364","name":"Institut National Du Cancer","doi-asserted-by":"publisher","award":["18-127"],"award-info":[{"award-number":["18-127"]}],"id":[{"id":"10.13039\/501100006364","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Between 30% and 70% of patients with breast cancer have pre-existing chronic conditions, and more than half are on long-term non-cancer medication at the time of diagnosis. Preliminary epidemiological evidence suggests that some non-cancer medications may affect breast cancer risk, recurrence, and survival. In this nationwide cohort study, we assessed the association between medication use at breast cancer diagnosis and survival. We included 235,368 French women with newly diagnosed non-metastatic breast cancer. In analyzes of 288 medications, we identified eight medications positively associated with either overall survival or disease-free survival: rabeprazole, alverine, atenolol, simvastatin, rosuvastatin, estriol (vaginal or transmucosal), nomegestrol, and hypromellose; and eight medications negatively associated with overall survival or disease-free survival: ferrous fumarate, prednisolone, carbimazole, pristinamycin, oxazepam, alprazolam, hydroxyzine, and mianserin. Full results are available online from an interactive platform (<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/adrenaline.curie.fr\">https:\/\/adrenaline.curie.fr<\/jats:ext-link>). This resource provides hypotheses for drugs that may naturally influence breast cancer evolution.<\/jats:p>","DOI":"10.1038\/s41467-024-47002-3","type":"journal-article","created":{"date-parts":[[2024,4,5]],"date-time":"2024-04-05T18:01:54Z","timestamp":1712340114000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Concomitant medication, comorbidity and survival in patients with breast cancer"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7877-719X","authenticated-orcid":false,"given":"Elise","family":"Dumas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Grandal Rejo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Gougis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Houzard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5818-8304","authenticated-orcid":false,"given":"Judith","family":"Ab\u00e9cassis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Floriane","family":"Jochum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Marande","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annabelle","family":"Ballesta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9654-5202","authenticated-orcid":false,"given":"Elaine","family":"Del Nery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4739-6164","authenticated-orcid":false,"given":"Thierry","family":"Dubois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0060-1346","authenticated-orcid":false,"given":"Samar","family":"Alsafadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Asselain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9218-0333","authenticated-orcid":false,"given":"Aur\u00e9lien","family":"Latouche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Espie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enora","family":"Laas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Coussy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cl\u00e9mentine","family":"Bouchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Yves","family":"Pierga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Le Bihan-Benjamin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0217-5483","authenticated-orcid":false,"given":"Philippe-Jean","family":"Bousquet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judica\u00ebl","family":"Hotton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1003-301X","authenticated-orcid":false,"given":"Chlo\u00e9-Agathe","family":"Azencott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2318-3589","authenticated-orcid":false,"given":"Fabien","family":"Reyal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Sophie","family":"Hamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,5]]},"reference":[{"key":"47002_CR1","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1093\/aje\/kws580","volume":"178","author":"H Cho","year":"2013","unstructured":"Cho, H., Mariotto, A. B., Mann, B. S., Klabunde, C. N. & Feuer, E. J. Assessing non-cancer-related health status of US cancer patients: other-cause survival and comorbidity prevalence. Am. J. Epidemiol. 178, 339\u2013349 (2013).","journal-title":"Am. J. Epidemiol."},{"key":"47002_CR2","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1111\/jgs.12687","volume":"62","author":"G Kimmick","year":"2014","unstructured":"Kimmick, G. et al. Comorbidity burden and guideline-concordant care for breast cancer. J. Am. Geriatr. Soc. 62, 482\u2013488 (2014).","journal-title":"J. Am. Geriatr. Soc."},{"key":"47002_CR3","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1093\/jnci\/djr188","volume":"103","author":"JL Patnaik","year":"2011","unstructured":"Patnaik, J. L., Byers, T., DiGuiseppi, C., Denberg, T. D. & Dabelea, D. The influence of comorbidities on overall survival among older women diagnosed with breast cancer. J. Natl Cancer Inst. 103, 1101\u20131111 (2011).","journal-title":"J. Natl Cancer Inst."},{"key":"47002_CR4","doi-asserted-by":"publisher","first-page":"E7962","DOI":"10.3390\/ijerph17217962","volume":"17","author":"PS Aye","year":"2020","unstructured":"Aye, P. S. et al. Use of non-cancer medications in new zealand women at the diagnosis of primary invasive breast cancer: prevalence, associated factors and effects on survival. Int J. Environ. Res Public Health 17, E7962 (2020).","journal-title":"Int J. Environ. Res Public Health"},{"key":"47002_CR5","doi-asserted-by":"publisher","first-page":"e451","DOI":"10.1200\/JOP.2016.018317","volume":"13","author":"GS Calip","year":"2017","unstructured":"Calip, G. S. et al. Polypharmacy and adherence to adjuvant endocrine therapy for breast cancer. JOP 13, e451\u2013e462 (2017).","journal-title":"JOP"},{"key":"47002_CR6","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.canep.2017.05.010","volume":"49","author":"O Par\u00e9s-Badell","year":"2017","unstructured":"Par\u00e9s-Badell, O., Banqu\u00e9, M., Maci\u00e0, F., Castells, X. & Sala, M. Impact of comorbidity on survival by tumour location: Breast, colorectal and lung cancer (2000-2014). Cancer Epidemiol. 49, 66\u201374 (2017).","journal-title":"Cancer Epidemiol."},{"key":"47002_CR7","doi-asserted-by":"publisher","first-page":"2332","DOI":"10.1038\/sj.bjc.6601844","volume":"90","author":"S Houterman","year":"2004","unstructured":"Houterman, S. et al. Comorbidity has negligible impact on treatment and complications but influences survival in breast cancer patients. Br. J. Cancer 90, 2332\u20132337 (2004).","journal-title":"Br. J. Cancer"},{"key":"47002_CR8","first-page":"1","volume":"3","author":"Y Wu","year":"2019","unstructured":"Wu, Y. et al. Discovery of noncancer drug effects on survival in electronic health records of patients with cancer: a new paradigm for drug repurposing. JCO Clin. Cancer Inf. 3, 1\u20139 (2019).","journal-title":"JCO Clin. Cancer Inf."},{"key":"47002_CR9","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s10549-008-0228-6","volume":"117","author":"Y Zhao","year":"2009","unstructured":"Zhao, Y. et al. Association between NSAIDs use and breast cancer risk: a systematic review and meta-analysis. Breast Cancer Res. Treat. 117, 141\u2013150 (2009).","journal-title":"Breast Cancer Res. Treat."},{"key":"47002_CR10","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1093\/jnci\/djr291","volume":"103","author":"TP Ahern","year":"2011","unstructured":"Ahern, T. P. et al. Statin prescriptions and breast cancer recurrence risk: a Danish nationwide prospective cohort study. J. Natl Cancer Inst. 103, 1461\u20131468 (2011).","journal-title":"J. Natl Cancer Inst."},{"key":"47002_CR11","doi-asserted-by":"publisher","unstructured":"Haukka, J., Niskanen, L. & Auvinen, A. Risk of cause-specific death in individuals with cancer-modifying role diabetes, statins and metformin. Int. J. Cancer https:\/\/doi.org\/10.1002\/ijc.31016 (2017).","DOI":"10.1002\/ijc.31016"},{"key":"47002_CR12","doi-asserted-by":"publisher","first-page":"2635","DOI":"10.1200\/JCO.2010.33.5422","volume":"29","author":"TI Barron","year":"2011","unstructured":"Barron, T. I., Connolly, R. M., Sharp, L., Bennett, K. & Visvanathan, K. Beta blockers and breast cancer mortality: a population- based study. J. Clin. Oncol. 29, 2635\u20132644 (2011).","journal-title":"J. Clin. Oncol."},{"key":"47002_CR13","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1038\/nrclinonc.2011.123","volume":"8","author":"DG Powe","year":"2011","unstructured":"Powe, D. G. & Entschladen, F. Using \u03b2-blockers to inhibit breast cancer progression: Targeted therapies. Nat. Rev. Clin. Oncol. 8, 511\u2013512 (2011).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"47002_CR14","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1093\/humupd\/dmi028","volume":"11","author":"JA Collins","year":"2005","unstructured":"Collins, J. A., Blake, J. M. & Crosignani, P. G. Breast cancer risk with postmenopausal hormonal treatment. Hum. Reprod. Update 11, 545\u2013560 (2005).","journal-title":"Hum. Reprod. Update"},{"key":"47002_CR15","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1158\/1055-9965.EPI-20-1028","volume":"30","author":"NC St\u00f8er","year":"2021","unstructured":"St\u00f8er, N. C. et al. Drug use and cancer risk: a drug-wide association study (DWAS) in Norway. Cancer Epidemiol. Biomark. Prev. 30, 682\u2013689 (2021).","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"47002_CR16","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1053\/ctrv.2001.0228","volume":"27","author":"AF Baker","year":"2001","unstructured":"Baker, A. F. & Dorr, R. T. Drug interactions with the taxanes: clinical implications. Cancer Treat. Rev. 27, 221\u2013233 (2001).","journal-title":"Cancer Treat. Rev."},{"key":"47002_CR17","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1200\/JCO.18.00636","volume":"37","author":"A-S Hamy","year":"2019","unstructured":"Hamy, A.-S. et al. Celecoxib with neoadjuvant chemotherapy for breast cancer might worsen outcomes differentially by cox-2 expression and er status: exploratory analysis of the REMAGUS02 trial. JCO 37, 624\u2013635 (2019).","journal-title":"JCO"},{"key":"47002_CR18","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1177\/1078155210379167","volume":"17","author":"T Tyler","year":"2011","unstructured":"Tyler, T. Drug interactions in metastatic breast cancer. J. Oncol. Pharm. Pr. 17, 236\u2013245 (2011).","journal-title":"J. Oncol. Pharm. Pr."},{"key":"47002_CR19","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1177\/1078155220963212","volume":"27","author":"R Bibi","year":"2021","unstructured":"Bibi, R. et al. Prevalence of potential drug-drug interactions in breast cancer patients and determination of their risk factors. J. Oncol. Pharm. Pr. 27, 1616\u20131622 (2021).","journal-title":"J. Oncol. Pharm. Pr."},{"key":"47002_CR20","doi-asserted-by":"publisher","first-page":"S149","DOI":"10.1016\/j.respe.2017.05.004","volume":"65","author":"P Tuppin","year":"2017","unstructured":"Tuppin, P. et al. Value of a national administrative database to guide public decisions: From the syst\u00e8me national d\u2019information interr\u00e9gimes de l\u2019Assurance Maladie (SNIIRAM) to the syst\u00e8me national des donn\u00e9es de sant\u00e9 (SNDS) in France. Rev. Epidemiol. Sante Publique 65, S149\u2013S167 (2017).","journal-title":"Rev. Epidemiol. Sante Publique"},{"key":"47002_CR21","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1002\/pds.4233","volume":"26","author":"J Bezin","year":"2017","unstructured":"Bezin, J. et al. The national healthcare system claims databases in France, SNIIRAM and EGB: Powerful tools for pharmacoepidemiology. Pharmacoepidemiol Drug Saf. 26, 954\u2013962 (2017).","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"47002_CR22","first-page":"411","volume":"36","author":"G Moulis","year":"2015","unstructured":"Moulis, G. et al. French health insurance databases: what interest for medical research? La Revue de M\u00e9. decine Interne 36, 411\u2013417 (2015).","journal-title":"decine Interne"},{"key":"47002_CR23","doi-asserted-by":"publisher","first-page":"2671","DOI":"10.3390\/cancers14112671","volume":"14","author":"E Dumas","year":"2022","unstructured":"Dumas, E. et al. The french early breast cancer cohort (fresh): a resource for breast cancer research and evaluations of oncology practices based on the french national healthcare system database (SNDS). Cancers (Basel) 14, 2671 (2022).","journal-title":"Cancers (Basel)"},{"key":"47002_CR24","doi-asserted-by":"publisher","first-page":"7399","DOI":"10.1200\/JCO.2004.00.9753","volume":"23","author":"JM Geraci","year":"2005","unstructured":"Geraci, J. M., Escalante, C. P., Freeman, J. L. & Goodwin, J. S. Comorbid disease and cancer: the need for more relevant conceptual models in health services research. JCO 23, 7399\u20137404 (2005).","journal-title":"JCO"},{"key":"47002_CR25","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1097\/MLR.0000000000000471","volume":"54","author":"A Bannay","year":"2016","unstructured":"Bannay, A. et al. The best use of the charlson comorbidity index with electronic health care database to predict mortality. Med Care 54, 188\u2013194 (2016).","journal-title":"Med Care"},{"key":"47002_CR26","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1007\/s40263-018-0537-1","volume":"32","author":"S Billioti de Gage","year":"2018","unstructured":"Billioti de Gage, S. et al. Antidepressants and hepatotoxicity: a cohort study among 5 million individuals registered in the french national health insurance database. CNS Drugs 32, 673\u2013684 (2018).","journal-title":"CNS Drugs"},{"key":"47002_CR27","doi-asserted-by":"publisher","unstructured":"Bouyer, B., Rudnichi, A., Dray-Spira, R., Zureik, M. & Coste, J. Thromboembolic risk after lumbar spine surgery: a cohort study on 325 000 French patients. J. Thromb. Haemost. https:\/\/doi.org\/10.1111\/jth.14205 (2018).","DOI":"10.1111\/jth.14205"},{"key":"47002_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-74409-x","volume":"10","author":"J Coste","year":"2020","unstructured":"Coste, J. et al. Risk of early neurodevelopmental disorders associated with in utero exposure to valproate and other antiepileptic drugs: a nationwide cohort study in France. Sci. Rep. 10, 17362 (2020).","journal-title":"Sci. Rep."},{"key":"47002_CR29","doi-asserted-by":"publisher","first-page":"3516","DOI":"10.1093\/eurheartj\/ehz458","volume":"40","author":"P Giral","year":"2019","unstructured":"Giral, P., Neumann, A., Weill, A. & Coste, J. Cardiovascular effect of discontinuing statins for primary prevention at the age of 75 years: a nationwide population-based cohort study in France. Eur. Heart J. 40, 3516\u20133525 (2019).","journal-title":"Eur. Heart J."},{"key":"47002_CR30","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1002\/ijc.33216","volume":"148","author":"MJ Jabagi","year":"2020","unstructured":"Jabagi, M. J. et al. Risk of secondary hematologic malignancies associated with breast cancer chemotherapy and G-CSF support: A nationwide population-based cohort. Int. J. Cancer 148, 375\u2013384 (2020).","journal-title":"Int. J. Cancer"},{"key":"47002_CR31","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1001\/jama.2017.16071","volume":"318","author":"M Lemaitre","year":"2017","unstructured":"Lemaitre, M. et al. Association between use of thiopurines or tumor necrosis factor antagonists alone or in combination and risk of lymphoma in patients with inflammatory bowel disease. JAMA 318, 1679\u20131686 (2017).","journal-title":"JAMA"},{"key":"47002_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-68304-8","volume":"10","author":"G Maura","year":"2020","unstructured":"Maura, G. et al. Oral anticoagulants and risk of acute liver injury in patients with nonvalvular atrial fibrillation: a propensity-weighted nationwide cohort study. Sci. Rep. 10, 11624 (2020).","journal-title":"Sci. Rep."},{"key":"47002_CR33","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1111\/bjd.16809","volume":"180","author":"E Sbidian","year":"2019","unstructured":"Sbidian, E., Mezzarobba, M., Weill, A., Coste, J. & Rudant, J. Persistence of treatment with biologics for patients with psoriasis: a real-world analysis of 16 545 biologic-na\u00efve patients from the French National Health Insurance database (SNIIRAM). Br. J. Dermatol 180, 86\u201393 (2019).","journal-title":"Br. J. Dermatol"},{"key":"47002_CR34","unstructured":"Semenzato, L. et al. Maladies chroniques, \u00e9tats de sant\u00e9 et risque d\u2019hospitalisation et de d\u00e9c\u00e8s hospitalier pour COVID-19 lors de la premi\u00e8re vague de l\u2019\u00e9pid\u00e9mie en France: \u00c9tude de cohorte de 66 millions de personnes. 41, https:\/\/www.epi-phare.fr\/app\/uploads\/2021\/02\/epiphare_risques_hospitalisations_deces_covid19_20210209.pdf (2021)."},{"key":"47002_CR35","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1007\/s10552-019-01203-0","volume":"30","author":"HS Ng","year":"2019","unstructured":"Ng, H. S., Vitry, A., Koczwara, B., Roder, D. & McBride, M. L. Patterns of comorbidities in women with breast cancer: a Canadian population-based study. Cancer Causes Control 30, 931\u2013941 (2019).","journal-title":"Cancer Causes Control"},{"key":"47002_CR36","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/s13046-015-0220-z","volume":"34","author":"B-Y Wang","year":"2015","unstructured":"Wang, B.-Y. et al. Intermittent high dose proton pump inhibitor enhances the antitumor effects of chemotherapy in metastatic breast cancer. J. Exp. Clin. Cancer Res. 34, 109 (2015).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"47002_CR37","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2019.1677427","volume":"9","author":"A-S Hamy","year":"2019","unstructured":"Hamy, A.-S. et al. Comedications influence immune infiltration and pathological response to neoadjuvant chemotherapy in breast cancer. OncoImmunology 9, 1677427 (2019).","journal-title":"OncoImmunology"},{"key":"47002_CR38","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-015-0735-2","volume":"13","author":"S Fais","year":"2015","unstructured":"Fais, S. Evidence-based support for the use of proton pump inhibitors in cancer therapy. J. Transl. Med 13, 368 (2015).","journal-title":"J. Transl. Med"},{"key":"47002_CR39","doi-asserted-by":"publisher","unstructured":"Lu, Z.-N., Tian, B. & Guo, X.-L. Repositioning of proton pump inhibitors in cancer therapy. Cancer Chemother. Pharmacol. 1\u201313 https:\/\/doi.org\/10.1007\/s00280-017-3426-2 (2017).","DOI":"10.1007\/s00280-017-3426-2"},{"key":"47002_CR40","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.semcancer.2017.01.003","volume":"43","author":"E Spugnini","year":"2017","unstructured":"Spugnini, E. & Fais, S. Proton pump inhibition and cancer therapeutics: a specific tumor targeting or it is a phenomenon secondary to a systemic buffering? Semin. Cancer Biol. 43, 111\u2013118 (2017).","journal-title":"Semin. Cancer Biol."},{"key":"47002_CR41","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1158\/1078-0432.CCR-11-0641","volume":"18","author":"SW Cole","year":"2012","unstructured":"Cole, S. W. & Sood, A. K. Molecular pathways: beta-adrenergic signaling in cancer. Clin. Cancer Res 18, 1201\u20131206 (2012).","journal-title":"Clin. Cancer Res"},{"key":"47002_CR42","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.1093\/annonc\/mdx264","volume":"28","author":"G Spera","year":"2017","unstructured":"Spera, G. et al. Beta blockers and improved progression-free survival in patients with advanced HER2 negative breast cancer: a retrospective analysis of the ROSE\/TRIO-012 study. Ann. Oncol. 28, 1836\u20131841 (2017).","journal-title":"Ann. Oncol."},{"key":"47002_CR43","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/j.clbc.2015.07.001","volume":"15","author":"WK Childers","year":"2015","unstructured":"Childers, W. K., Hollenbeak, C. S. & Cheriyath, P. \u03b2-Blockers reduce breast cancer recurrence and breast cancer death: a meta-analysis. Clin. Breast Cancer 15, 426\u2013431 (2015).","journal-title":"Clin. Breast Cancer"},{"key":"47002_CR44","doi-asserted-by":"publisher","first-page":"ed82","DOI":"10.3332\/ecancer.2018.ed82","volume":"12","author":"P Pantziarka","year":"2018","unstructured":"Pantziarka, P., Bryan, B. A., Crispino, S. & Dickerson, E. B. Propranolol and breast cancer\u2014a work in progress. ecancermedicalscience 12, ed82 (2018).","journal-title":"ecancermedicalscience"},{"key":"47002_CR45","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1038\/nrc1751","volume":"5","author":"M-F Demierre","year":"2005","unstructured":"Demierre, M.-F., Higgins, P. D. R., Gruber, S. B., Hawk, E. & Lippman, S. M. Statins and cancer prevention. Nat. Rev. Cancer 5, 930\u2013942 (2005).","journal-title":"Nat. Rev. Cancer"},{"key":"47002_CR46","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s10549-020-05749-5","volume":"183","author":"S Harborg","year":"2020","unstructured":"Harborg, S. et al. Statin use and breast cancer recurrence in postmenopausal women treated with adjuvant aromatase inhibitors: a Danish population-based cohort study. Breast Cancer Res Treat. 183, 153\u2013160 (2020).","journal-title":"Breast Cancer Res Treat."},{"key":"47002_CR47","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-018-5263-z","volume":"19","author":"S Borgquist","year":"2019","unstructured":"Borgquist, S., Broberg, P., Tojjar, J. & Olsson, H. Statin use and breast cancer survival \u2013 a Swedish nationwide study. BMC Cancer 19, 54 (2019).","journal-title":"BMC Cancer"},{"key":"47002_CR48","doi-asserted-by":"crossref","unstructured":"Collaborative Group on Hormonal Factors in Breast Cancer. Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence. Lancet 394, 1159\u20131168 (2019).","DOI":"10.1016\/S0140-6736(19)31709-X"},{"key":"47002_CR49","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1001\/jama.2020.9482","volume":"324","author":"RT Chlebowski","year":"2020","unstructured":"Chlebowski, R. T. et al. Association of menopausal hormone therapy with breast cancer incidence and mortality during long-term follow-up of the women\u2019s health initiative randomized clinical trials. JAMA 324, 369\u2013380 (2020).","journal-title":"JAMA"},{"key":"47002_CR50","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1001\/jamaoncol.2015.0494","volume":"1","author":"RT Chlebowski","year":"2015","unstructured":"Chlebowski, R. T. et al. Breast cancer after use of estrogen plus progestin and estrogen alone: analyses of data from 2 women\u2019s health initiative randomized clinical trials. JAMA Oncol. 1, 296\u2013305 (2015).","journal-title":"JAMA Oncol."},{"key":"47002_CR51","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/S1470-2045(08)70341-3","volume":"10","author":"P Kenemans","year":"2009","unstructured":"Kenemans, P. et al. Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomised, non-inferiority trial. Lancet Oncol. 10, 135\u2013146 (2009).","journal-title":"Lancet Oncol."},{"key":"47002_CR52","doi-asserted-by":"publisher","first-page":"347","DOI":"10.5694\/j.1326-5377.2002.tb04835.x","volume":"177","author":"EM Durna","year":"2002","unstructured":"Durna, E. M. et al. Hormone replacement therapy after a diagnosis of breast cancer: cancer recurrence and mortality. Med. J. Aust. 177, 347\u2013351 (2002).","journal-title":"Med. J. Aust."},{"key":"47002_CR53","doi-asserted-by":"publisher","unstructured":"McVicker, L. et al. Vaginal estrogen therapy use and survival in females with breast cancer. JAMA Oncol e234508 https:\/\/doi.org\/10.1001\/jamaoncol.2023.4508 (2023).","DOI":"10.1001\/jamaoncol.2023.4508"},{"key":"47002_CR54","doi-asserted-by":"publisher","unstructured":"Cold, S. et al. Systemic or vaginal hormone therapy after early breast cancer: a danish observational cohort study. JNCI: Journal of the National Cancer Institute djac112 (2022) https:\/\/doi.org\/10.1093\/jnci\/djac112.","DOI":"10.1093\/jnci\/djac112"},{"key":"47002_CR55","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/S1470-2045(08)70200-6","volume":"9","author":"X Huang","year":"2008","unstructured":"Huang, X. Does iron have a role in breast cancer? Lancet Oncol. 9, 803\u2013807 (2008).","journal-title":"Lancet Oncol."},{"key":"47002_CR56","doi-asserted-by":"publisher","first-page":"43ra56","DOI":"10.1126\/scitranslmed.3001127","volume":"2","author":"ZK Pinnix","year":"2010","unstructured":"Pinnix, Z. K. et al. Ferroportin and iron regulation in breast cancer progression and prognosis. Sci. Transl. Med 2, 43ra56 (2010).","journal-title":"Sci. Transl. Med"},{"key":"47002_CR57","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1002\/ijc.11240","volume":"106","author":"V Nadalin","year":"2003","unstructured":"Nadalin, V., Cotterchio, M. & Kreiger, N. Antihistamine use and breast cancer risk. Int. J. Cancer 106, 566\u2013568 (2003).","journal-title":"Int. J. Cancer"},{"key":"47002_CR58","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.breast.2019.07.002","volume":"47","author":"IH Kanbayti","year":"2019","unstructured":"Kanbayti, I. H., Rae, W. I. D., McEntee, M. F. & Ekpo, E. U. Are mammographic density phenotypes associated with breast cancer treatment response and clinical outcomes? a systematic review and meta-analysis. Breast 47, 62\u201376 (2019).","journal-title":"Breast"},{"key":"47002_CR59","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-020-01690-y","volume":"18","author":"H Yang","year":"2020","unstructured":"Yang, H. et al. Hyperthyroidism is associated with breast cancer risk and mammographic and genetic risk predictors. BMC Med. 18, 225 (2020).","journal-title":"BMC Med."},{"key":"47002_CR60","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1093\/annonc\/mdz206","volume":"30","author":"A Elkrief","year":"2019","unstructured":"Elkrief, A., Derosa, L., Kroemer, G., Zitvogel, L. & Routy, B. The negative impact of antibiotics on outcomes in cancer patients treated with immunotherapy: a new independent prognostic factor? Ann. Oncol. 30, 1572\u20131579 (2019).","journal-title":"Ann. Oncol."},{"key":"47002_CR61","doi-asserted-by":"publisher","first-page":"e0274675","DOI":"10.1371\/journal.pone.0274675","volume":"17","author":"M Crozier","year":"2022","unstructured":"Crozier, M. et al. Frequently used antiemetic agent dexamethasone enhances the metastatic behaviour of select breast cancer cells. PLOS ONE 17, e0274675 (2022).","journal-title":"PLOS ONE"},{"key":"47002_CR62","doi-asserted-by":"crossref","first-page":"117822342097466","DOI":"10.1177\/1178223420974667","volume":"14","author":"EM Zhidkova","year":"2020","unstructured":"Zhidkova, E. M. et al. A brief overview of the paradoxical role of glucocorticoids in breast cancer. Breast Cancer (Auckl.) 14, 1178223420974667 (2020).","journal-title":"Breast Cancer (Auckl.)"},{"key":"47002_CR63","doi-asserted-by":"publisher","first-page":"298","DOI":"10.3390\/curroncol30010024","volume":"30","author":"IB Mitre-Aguilar","year":"2022","unstructured":"Mitre-Aguilar, I. B. et al. The role of glucocorticoids in breast cancer therapy. Curr. Oncol. 30, 298\u2013314 (2022).","journal-title":"Curr. Oncol."},{"key":"47002_CR64","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-021-02004-6","volume":"19","author":"M Cairat","year":"2021","unstructured":"Cairat, M. et al. Use of systemic glucocorticoids and risk of breast cancer in a prospective cohort of postmenopausal women. BMC Med. 19, 186 (2021).","journal-title":"BMC Med."},{"key":"47002_CR65","doi-asserted-by":"publisher","first-page":"e483","DOI":"10.1097\/MD.0000000000000483","volume":"94","author":"U Iqbal","year":"2015","unstructured":"Iqbal, U. et al. Is Long-term use of benzodiazepine a risk for cancer? Med. (Baltim.) 94, e483 (2015).","journal-title":"Med. (Baltim.)"},{"key":"47002_CR66","doi-asserted-by":"publisher","first-page":"3793","DOI":"10.1158\/1078-0432.CCR-23-0547","volume":"29","author":"AC Cornwell","year":"2023","unstructured":"Cornwell, A. C. et al. Lorazepam stimulates il6 production and is associated with poor survival outcomes in pancreatic cancer. Clin. Cancer Res 29, 3793\u20133812 (2023).","journal-title":"Clin. Cancer Res"},{"key":"47002_CR67","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/nature15699","volume":"527","author":"X-P Huang","year":"2015","unstructured":"Huang, X.-P. et al. Allosteric ligands for the pharmacologically dark receptors GPR68 and GPR65. Nature 527, 477\u2013483 (2015).","journal-title":"Nature"},{"key":"47002_CR68","doi-asserted-by":"publisher","DOI":"10.1186\/1742-2094-8-68","volume":"8","author":"K Tanabe","year":"2011","unstructured":"Tanabe, K., Kozawa, O. & Iida, H. Midazolam suppresses interleukin-1\u03b2-induced interleukin-6 release from rat glial cells. J. Neuroinflammation 8, 68 (2011).","journal-title":"J. Neuroinflammation"},{"key":"47002_CR69","doi-asserted-by":"publisher","first-page":"e0206448","DOI":"10.1371\/journal.pone.0206448","volume":"13","author":"PJ Bousquet","year":"2018","unstructured":"Bousquet, P. J. et al. Cancer care and public health policy evaluations in France: Usefulness of the national cancer cohort. PLoS One 13, e0206448 (2018).","journal-title":"PLoS One"},{"key":"47002_CR70","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2458-9-33","volume":"9","author":"G Rey","year":"2009","unstructured":"Rey, G., Jougla, E., Fouillet, A. & H\u00e9mon, D. Ecological association between a deprivation index and mortality in France over the period 1997 \u2212 2001: variations with spatial scale, degree of urbanicity, age, gender and cause of death. BMC Public Health 9, 33 (2009).","journal-title":"BMC Public Health"},{"key":"47002_CR71","unstructured":"Hern\u00e1n, M. A. & Robins, J. M. Causal Inference: What If. (Boca Raton: Chapman & Hall\/CRC., 2020)."},{"key":"47002_CR72","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1080\/00273171.2011.568786","volume":"46","author":"PC Austin","year":"2011","unstructured":"Austin, P. C. An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies. Multivar. Behav. Res 46, 399\u2013424 (2011).","journal-title":"Multivar. Behav. Res"},{"key":"47002_CR73","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.cmpb.2003.10.004","volume":"75","author":"SR Cole","year":"2004","unstructured":"Cole, S. R. & Hern\u00e1n, M. A. Adjusted survival curves with inverse probability weights. Comput Methods Prog. Biomed. 75, 45\u201349 (2004).","journal-title":"Comput Methods Prog. Biomed."},{"key":"47002_CR74","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1097\/EDE.0000000000000034","volume":"25","author":"TJ VanderWeele","year":"2014","unstructured":"VanderWeele, T. J., Vansteelandt, S. & Robins, J. M. Effect decomposition in the presence of an exposure-induced mediator-outcome confounder. Epidemiology 25, 300\u2013306 (2014).","journal-title":"Epidemiology"},{"key":"47002_CR75","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-65917-x","volume":"10","author":"A Chatton","year":"2020","unstructured":"Chatton, A. et al. G-computation, propensity score-based methods, and targeted maximum likelihood estimator for causal inference with different covariates sets: a comparative simulation study. Sci. Rep. 10, 9219 (2020).","journal-title":"Sci. Rep."},{"key":"47002_CR76","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1002\/sim.6777","volume":"35","author":"F Le Borgne","year":"2016","unstructured":"Le Borgne, F., Giraudeau, B., Querard, A. H., Giral, M. & Foucher, Y. Comparisons of the performance of different statistical tests for time-to-event analysis with confounding factors: practical illustrations in kidney transplantation. Stat. Med 35, 1103\u20131116 (2016).","journal-title":"Stat. Med"},{"key":"47002_CR77","doi-asserted-by":"publisher","unstructured":"Dumas, E. Concomitant medication, comorbidity and survival in patients with breast cancer - rt2lab\/adrenaline: ADRENALINE - analysis code. Zenodo https:\/\/doi.org\/10.5281\/zenodo.10777521 (2024).","DOI":"10.5281\/zenodo.10777521"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-47002-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-47002-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-47002-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,5]],"date-time":"2024-04-05T19:02:35Z","timestamp":1712343755000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-47002-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,5]]},"references-count":77,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["47002"],"URL":"https:\/\/doi.org\/10.1038\/s41467-024-47002-3","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,5]]},"assertion":[{"value":"17 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2966"}}